- Home
- IACQ vs LXEO Comparison
IACQ vs LXEO Comparison
Compare IACQ & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Company Overview
Basic Information| Metric | IACQ | LXEO |
|---|---|---|
| Founded | 2026 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.4M | 348.7M |
| IPO Year | 2026 | 2023 |
Fundamental Metrics
Financial Performance| Metric | IACQ | LXEO |
|---|---|---|
| Price | $9.90 | $2.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $20.30 |
| AVG Volume (30 Days) | 84.7K | ★ 1.9M |
| Earning Date | N/A | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $2.56 |
| 52 Week High | $10.10 | $10.99 |
Technical Indicators
Market Signals| Indicator | IACQ | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 26.39 |
| Support Level | N/A | N/A |
| Resistance Level | $10.00 | $5.38 |
| Average True Range (ATR) | 0.01 | 0.26 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 10.00 | 11.61 |
Price Performance
Historical Comparison IACQ
LXEO
About IACQ Irenic Acquisition Corp. Class A Ordinary Shares
Irenic Acquisition Corp is a blank check company with no operations.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.